Data / Drug companies / Verapamil hydrochloride
Verapamil hydrochloride: 46 companies and 132 products in the FDA NDC directory
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Verapamil hydrochloride is listed in the FDA National Drug Code Directory by 46 companies, with 132 products in commercial distribution. 121 of the products (91.7%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are tablet; injection, solution; tablet, film coated, extended release, and the newest product started marketing on May 21, 2026.
The request: Get every company that lists verapamil hydrochloride in the FDA NDC directory, with headquarters, website and number of employees. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 46
- Products
- 132
- Generic (ANDA) products
- 121 (91.7%)
- Application numbers
- 26
- Routes
- Oral, Intravenous
- openFDA record search
- api.fda.gov
Companies that list verapamil hydrochloride
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Medical Purchasing Solutions, LLC | 7 | injection; injection, solution | Generic drugs (ANDA) | June 16, 2022 |
| Wilshire Pharmaceuticals, Inc. | 7 | capsule, delayed release; capsule, extended release | Authorized generics (NDA) | November 26, 2024 |
| Bryant Ranch Prepack | 6 | tablet; tablet, film coated | Generic drugs (ANDA) | January 2, 2023 |
| Northwind Health Company, LLC | 6 | tablet; tablet, film coated, extended release | Generic drugs (ANDA) | January 31, 2023 |
| NuCare Pharmaceuticals,Inc. | 6 | tablet; tablet, film coated, extended release | Generic drugs (ANDA) | May 15, 2019 |
| A-S Medication Solutions | 5 | tablet, film coated, extended release; tablet | Generic drugs (ANDA) | January 2, 2023 |
| HF Acquisition Co LLC, DBA HealthFirst | 5 | injection, solution | Generic drugs (ANDA) | May 20, 2022 |
| Heritage Pharmaceuticals Inc. D/B/A Avet Pharmaceuticals Inc. | 5 | tablet; injection | Generic drugs (ANDA) | January 15, 2025 |
| Zydus Lifesciences Limited | 5 | tablet; injection, solution | Generic drugs (ANDA) | May 21, 2026 |
| Chartwell RX, LLC | 4 | tablet; capsule, extended release | Generic drugs (ANDA) | July 20, 2018 |
| Preferred Pharmaceuticals Inc. | 4 | tablet, film coated, extended release; tablet | Generic drugs (ANDA) | June 11, 2024 |
| Remedyrepack Inc. | 4 | tablet, film coated, extended release; injection, solution | Generic drugs (ANDA) | November 1, 2025 |
| Actavis Pharma, Inc. | 3 | tablet, film coated | Generic drugs (ANDA) | June 29, 1993 |
| AvKARE | 3 | tablet | Generic drugs (ANDA) | April 13, 2020 |
| Cadila Pharmaceuticals Limited | 3 | tablet, extended release | Generic drugs (ANDA) | May 27, 2017 |
| Glenmark Pharmaceuticals Inc., USA | 3 | tablet, film coated, extended release | Generic drugs (ANDA) | August 5, 2011 |
| Golden State Medical Supply, Inc. | 3 | tablet | Generic drugs (ANDA) | October 14, 2015 |
| Hospira, Inc. | 3 | injection, solution | Generic drugs (ANDA) | June 20, 2018 |
| Mylan Pharmaceuticals Inc. | 3 | capsule, extended release | Generic drugs (ANDA) | May 20, 1999 |
| Nivagen Pharmaceuticals, Inc. | 3 | tablet, film coated, extended release | Generic drugs (ANDA) | January 2, 2023 |
| Proficient Rx LP | 3 | tablet, film coated; tablet, film coated, extended release | Generic drugs (ANDA) | May 15, 2019 |
| Somerset Therapeutics, LLC | 3 | injection, solution | Generic drugs (ANDA) | June 18, 2018 |
| Zydus Pharmaceuticals USA Inc. | 3 | injection, solution | Generic drugs (ANDA) | October 17, 2023 |
| Zydus Pharmaceuticals USA Inc. | 3 | tablet | Generic drugs (ANDA) | May 21, 2026 |
| Amneal Pharmaceuticals LLC | 2 | injection, solution | Generic drugs (ANDA) | July 17, 2018 |
| Aphena Pharma Solutions - Tennessee, LLC | 2 | tablet, film coated, extended release; tablet | Generic drugs (ANDA) | May 15, 2019 |
| Armas Pharmaceuticals Inc. | 2 | injection | Generic drugs (ANDA) | January 1, 2020 |
| Baxter Healthcare Corporation | 2 | injection, solution | Generic drugs (ANDA) | March 25, 2020 |
| Caplin Steriles Limited | 2 | injection, solution | Generic drugs (ANDA) | January 16, 2025 |
| Eugia US LLC | 2 | injection, solution | Generic drugs (ANDA) | July 6, 2020 |
| Exela Pharma Sciences, LLC | 2 | injection | New drug applications (NDA) | February 1, 2017 |
| Gland Pharma Limited | 2 | injection | Generic drugs (ANDA) | October 15, 2020 |
| Henry Schein, Inc. | 2 | injection, solution | Generic drugs (ANDA) | January 11, 2022 |
| Lifestar Pharma LLC | 2 | injection, solution | Generic drugs (ANDA) | June 16, 2022 |
| Bryant Ranch Prepack | 1 | tablet | Generic drugs (ANDA) | January 7, 2011 |
| Bryant Ranch Prepack | 1 | tablet, film coated | Generic drugs (ANDA) | October 1, 1986 |
| Fresenius Kabi USA, LLC | 1 | injection | Generic drugs (ANDA) | November 25, 2024 |
| Micro Labs Limited | 1 | injection | Generic drugs (ANDA) | March 4, 2019 |
| Mylan Institutional Inc. | 1 | capsule, extended release | Generic drugs (ANDA) | October 1, 1999 |
| NuCare Pharmaceuticals, Inc. | 1 | tablet, film coated, extended release | Generic drugs (ANDA) | September 17, 2009 |
| PD-Rx Pharmaceuticals, Inc. | 1 | tablet, film coated, extended release | Generic drugs (ANDA) | September 17, 2009 |
| PD-Rx Pharmaceuticals, Inc. | 1 | tablet, film coated, extended release | Generic drugs (ANDA) | August 5, 2011 |
| ProPharma Distribution | 1 | injection, solution | Generic drugs (ANDA) | June 16, 2022 |
| Proficient Rx LP | 1 | tablet, film coated, extended release | Generic drugs (ANDA) | August 5, 2011 |
| Safecor Health, LLC | 1 | capsule, extended release | Generic drugs (ANDA) | May 5, 2026 |
| Sagent Pharmaceuticals | 1 | injection, solution | Generic drugs (ANDA) | March 15, 2021 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 38 | 28.8% |
| Injection, solution | 34 | 25.8% |
| Tablet, film coated, extended release | 22 | 16.7% |
| Injection | 14 | 10.6% |
| Capsule, extended release | 9 | 6.8% |
| Tablet, film coated | 8 | 6.1% |
| Capsule, delayed release | 4 | 3% |
| Tablet, extended release | 3 | 2.3% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 121 | 91.7% |
| Authorized generics (NDA) | 8 | 6.1% |
| New drug applications (NDA) | 3 | 2.3% |
Pharmacologic classes
| Class | Products |
|---|---|
| Calcium Channel Blocker | 132 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.